Literature DB >> 23148188

Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.

Bertha Pangaribuan, Irawan Yusuf, Muchtaruddin Mansyur, Andi Wijaya.   

Abstract

OBJECTIVE: The role of insulin resistance in polycystic ovary syndrome (PCOS) has been established. However the role of adiponectin and resistin in the relationship between insulin resistance as markers of obesity and PCOS has not been conclusive. This study aims to determine the influence of the serum levels of adiponectin and resistin on PCOS, and assess possible correlations with the hormonal and metabolic parameters of the syndrome and obesity.
METHODS: This study continued a case control study that had finished recruiting 24 subjects of reproductive women with PCOS as a case group, and 24 subjects of normal ovulatory reproductive women without hyperandrogenism as a control group. Further, only 18 subjects of the control group had a body mass index (BMI) <25 kg/m(2) and were included the data analysis, whereas others were excluded. Therefore, these study data were divided into three groups. Twenty-four PCOS patients from the case group were allocated to two groups, A (n = 14) patients had PCOS + BMI ≥25 kg/m(2); B (n = 10) patients had PCOS + BMI <25 kg/m(2). Group C was the control group of 18 reproductive women without PCOS + BMI <25 kg/m(2). Blood samples were collected between day 3 and 5 of a spontaneous menstrual cycle, at 07:00 to 09:00, after overnight fasting. Serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone, prolactin, sex hormone-binding globulin (SHBG), glucose, insulin, adiponectin and resistin were measured.
RESULTS: Serum adiponectin levels were significantly decreased in group A compared with group B and group C. No significant difference existed in adiponectin between group B and group C. Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR) value in group A was found to be significantly higher than group C, but no significant differences were found between group B and group C or between group A and group B. There was no significant difference in serum resistin between all groups, nevertheless the resistin-to-adiponectin (R:A) ratio was significantly decreased in group A compared with groups B and C. In a multiple regression model, BMI, testosterone and insulin resistance were the major determinants of hypoadiponectinemia. However, only BMI was the major determinant of the resistin represented by the R:A ratio.
CONCLUSIONS: Serum adiponectin levels and the ratio of resistin to adiponectin levels are reduced in obese women with PCOS. These results suggest that, by reducing adiponectin serum level, hyperandrogenemia, together with nutritional status of obesity, might contribute to insulin resistance in the pathogenesis of PCOS.

Entities:  

Keywords:  adiponectin; insulin resistance; obesity; polycystic ovary syndrome; resistin

Year:  2011        PMID: 23148188      PMCID: PMC3474644          DOI: 10.1177/2042018811423770

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  24 in total

1.  Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome.

Authors:  Nectaria Xita; Ioannis Georgiou; Anthoula Chatzikyriakidou; Maria Vounatsou; Gerasimos-Peter Papassotiriou; Ioannis Papassotiriou; Agathocles Tsatsoulis
Journal:  Clin Chem       Date:  2004-12-08       Impact factor: 8.327

2.  The hormone resistin links obesity to diabetes.

Authors:  C M Steppan; S T Bailey; S Bhat; E J Brown; R R Banerjee; C M Wright; H R Patel; R S Ahima; M A Lazar
Journal:  Nature       Date:  2001-01-18       Impact factor: 49.962

Review 3.  Is obesity an inflammatory condition?

Authors:  U N Das
Journal:  Nutrition       Date:  2001 Nov-Dec       Impact factor: 4.008

4.  Resistin, an adipokine with potent proinflammatory properties.

Authors:  Maria Bokarewa; Ivan Nagaev; Leif Dahlberg; Ulf Smith; Andrej Tarkowski
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

5.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

Authors:  K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

6.  FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family.

Authors:  I N Holcomb; R C Kabakoff; B Chan; T W Baker; A Gurney; W Henzel; C Nelson; H B Lowman; B D Wright; N J Skelton; G D Frantz; D B Tumas; F V Peale; D L Shelton; C C Hébert
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

Review 7.  ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism.

Authors:  Anders H Berg; Terry P Combs; Philipp E Scherer
Journal:  Trends Endocrinol Metab       Date:  2002-03       Impact factor: 12.015

8.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Authors:  C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

9.  Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.

Authors:  Vicken Sepilian; Manubai Nagamani
Journal:  J Soc Gynecol Investig       Date:  2005-02

10.  Serum adiponectin levels in women with polycystic ovary syndrome.

Authors:  Dimitrios Panidis; Anargyros Kourtis; Dimitrios Farmakiotis; Tzant Mouslech; David Rousso; Georgios Koliakos
Journal:  Hum Reprod       Date:  2003-09       Impact factor: 6.918

View more
  9 in total

1.  Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis.

Authors:  Shan Li; Xiamei Huang; Huizhi Zhong; Qiliu Peng; Siyuan Chen; Yantong Xie; Xue Qin; Aiping Qin
Journal:  Tumour Biol       Date:  2014-01-12

2.  Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.

Authors:  Sehresh Hassan; Mohsin Shah; Muhammad Omar Malik; Ehtesham Ehtesham; Syed Hamid Habib; Bushra Rauf
Journal:  Endocrine       Date:  2022-09-28       Impact factor: 3.925

3.  Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.

Authors:  Saman Tauqir; Momina Israr; Bushra Rauf; Muhammad Omar Malik; Syed Hamid Habib; Fawad Ali Shah; Muhammad Usman; Muhammad Asif Raza; Inayat Shah; Haroon Badshah; Ehtesham Ehtesham; Mohsin Shah
Journal:  Adv Ther       Date:  2021-05-28       Impact factor: 3.845

4.  Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients.

Authors:  R Dehghan; M Saidijam; N Shabab; M Yavangi; T Artimani
Journal:  J Endocrinol Invest       Date:  2016-04-13       Impact factor: 4.256

5.  Blood Circulating Levels of Adipokines in Polycystic Ovary Syndrome Patients: A Systematic Review and Meta-analysis.

Authors:  Sanaz Mehrabani; Arman Arab; Elham Karimi; Mehran Nouri; Marjan Mansourian
Journal:  Reprod Sci       Date:  2021-09-01       Impact factor: 2.924

Review 6.  N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials.

Authors:  Divyesh Thakker; Amit Raval; Isha Patel; Rama Walia
Journal:  Obstet Gynecol Int       Date:  2015-01-08

7.  Evaluation of relationship between serum levels of anti-müllerian hormone, androgen, and insulin resistant with retrieval oocytes in overweight patients with polycystic ovary syndrome.

Authors:  Esmat Aghadavod; Nosratollah Zarghami; Laya Farzadi; Mina Zare; Abolfazl Barzegari; Ali Akbar Movassaghpour; Mohammad Nouri
Journal:  Adv Biomed Res       Date:  2015-03-25

Review 8.  New markers of insulin resistance in polycystic ovary syndrome.

Authors:  K Polak; A Czyzyk; T Simoncini; B Meczekalski
Journal:  J Endocrinol Invest       Date:  2016-07-29       Impact factor: 4.256

9.  Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis.

Authors:  Tahereh Raeisi; Hossein Rezaie; Mina Darand; Akram Taheri; Nazila Garousi; Bahman Razi; Leonardo Roever; Reza Mohseni; Shimels Hussien Mohammed; Shahab Alizadeh
Journal:  PLoS One       Date:  2021-03-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.